Sonoran Biosciences, Inc. is focused on developing innovative pharmaceutical solutions aimed at addressing postoperative pain and preventing surgical site infections (SSIs). Their lead products include SBG004, a sustained-release local anesthetic designed to provide effective pain relief for up to 72 hours post-surgery, and SBG003, an antimicrobial formulation intended to maintain high antibiotic concentrations at surgical sites to combat infection. The company utilizes a proprietary biomaterial known as SB Gel, which is a temperature-responsive polymer that forms a hydrogel at body temperature, allowing for localized and sustained drug delivery directly to the surgical area. This technology aims to enhance patient recovery by minimizing the reliance on opioids and reducing the risk of SSIs, which are significant concerns in surgical procedures.

The SBG004 formulation leverages the unique properties of SB Gel to create a depot of local anesthetic that ensures prolonged analgesia while maintaining effective drug distribution in the surrounding tissue. This approach addresses the limitations of traditional local anesthetics, which typically have a short duration of action. Similarly, SBG003 is designed to provide a sustained release of antibiotics, targeting the prevention of SSIs that can arise from bacterial presence at the surgical site. By focusing on localized drug delivery, Sonoran Biosciences aims to improve patient outcomes and reduce healthcare costs associated with postoperative complications.

United States

Sonoran Biosciences is a preclinical-stage pharmaceutical company that develops antibacterial gel for the treatment of surgical site infection.

Sonoran Biosciences, Inc

Company Details